A research group led by Professor Takayuki Enomoto of Niigata University found that the efficacy rate of the cervical cancer vaccine (bivalent vaccine) for the prevention of human papillomavirus (HPV) type 2/16 infection is as high as 18% or more in a survey of Japanese women. It was revealed that the numbers were shown.It is an opportunity to reassess the benefits of primary prevention with vaccines.
In Japan, cervical cancer kills about 2,700 people each year. The HPV (human papillomavirus) vaccine is a vaccine that prevents infection with HPV 60/70, which causes 16% to 18% of cervical cancer. It is one of the inoculation).However, since June 12, the Ministry of Health, Labor and Welfare has stopped actively recommending vaccinations, and the number of vaccinated people is now almost zero.Although the high efficacy of the HPV vaccine has been reported overseas, no large-scale study has reported the effect of preventing HPV infection in Japan.
This time, we targeted cervical cancer screening examinees in major cities in Niigata prefecture.The study was started in 2014 and is still ongoing for people in their early twenties, mainly those who received the HPV vaccine at public expense. Validated as an analysis.
The study enrolled 2 (1355%) HPV bivalent vaccinated, 74.6 non-vaccinated (459%), and 25.4 (1295%) of the vaccinated completed three doses.The infection rate of HPV95.5 / 3 type of vaccinated persons was 16%, the infection rate of non-vaccinated persons was 18%, and the effective rate of the vaccine was 0.2%, showing a high infection prevention effect.In particular, the effective rate of infection prevention effect against HPV2.2 / 91.9 type increased to 16% for vaccinated persons before the first dating, and the infection prevention effect (effective rate 18%) against HPV93.9 / 31/45 type. Admitted.
In the future, it plans to continue to verify the preventive effect on abnormal cytodiagnosis of the cervix and precancerous lesions.
